Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Increased levels of CSF CD59 in neuromyelitis optica and multiple sclerosis.
Alphab-crystallin is a target for adaptive immune responses and a trigger of innate responses in preactive multiple sclerosis lesions.
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.
Effects of Eight-week Resistance Training Program in Men With Multiple Sclerosis.
Development of Ms Budget Manager: A Practical Tool to Assist Alternative Stakeholders At Multiple Decision Levels In The Forecast And Financial Management For Multiple Sclerosis (Ms).
Development of A Screening Tool to Support Identification of Patients With Secondary Progressive Multiple Sclerosis (Spms).
Patterns Of Use Of Tests To Monitor Disease Activity Among Patients Currently Treated For Relapsing Remitting Multiple Sclerosis (Rrms) In Europe.
Acute Respiratory Failure due to Neuromyelitis Optica Treated Successfully with Plasmapheresis.
Cell death of spinal cord ED1(+) cells in a rat model of multiple sclerosis.
Highly polarized Th17 cells induce EAE via a T-bet-independent mechanism.
Transdermal immunotherapy: Past, present and future.
Rituximab in Turkish neuromyelitis optica patients with limited response to other immunosuppressants.
Influence of Formal Education on Cognitive Reserve in Patients with Multiple Sclerosis.
Antibody therapies in CNS diseases.
Clinical perspectives of TRAIL: insights into central nervous system disorders.
Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders.
Cost-Effectiveness of New Therapies for Multiple Sclerosis In Spain.
Deep morphea induced by interferon-β1b injection.
Fingolimod and cardiac risk: latest findings and clinical implications.
Protein misfolding and clearance in demyelinating peripheral neuropathies: Therapeutic implications.
Peloruside A: a lead non-taxoid-site microtubule-stabilizing agent with potential activity against cancer, neurodegeneration, and autoimmune disease.
Overactive Bladder Syndrome, Detrusor Overactivity and the Botulinum Toxin.
Disease Activity during the First Year Predicts Clinical Long-Term Outcomes in Patients with Multiple Sclerosis: Fingolimod Treatment Benefit
Budget Impact Analysis of Delayed-Release Dimethylfumarate In The Treatment of Relapsing-Remitting Multiple Sclerosis In Italy.
[Target Molecule for a Demyelinating Type of Guillain-Barré Syndrome, Acute Inflammatory Demyelinating Polyneuropathy].

Pages